GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Q-linea AB (OSTO:QLINEA) » Definitions » ROE % Adjusted to Book Value

Q-linea AB (OSTO:QLINEA) ROE % Adjusted to Book Value : -247.45% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Q-linea AB ROE % Adjusted to Book Value?

Q-linea AB's ROE % for the quarter that ended in Mar. 2025 was -390.97%. Q-linea AB's PB Ratio for the quarter that ended in Mar. 2025 was 1.58. Q-linea AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 was -247.45%.


Q-linea AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Q-linea AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q-linea AB ROE % Adjusted to Book Value Chart

Q-linea AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.02 -7.44 -48.15 -57.03 -

Q-linea AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.03 -36.75 -27.11 - -247.45

Competitive Comparison of Q-linea AB's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Q-linea AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q-linea AB's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Q-linea AB's ROE % Adjusted to Book Value falls into.


;
;

Q-linea AB ROE % Adjusted to Book Value Calculation

Q-linea AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-267.45% / N/A
=N/A

Q-linea AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-390.97% / 1.58
=-247.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Q-linea AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Q-linea AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Q-linea AB Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.

Q-linea AB Headlines

No Headlines